Stocks Health care CRDL
NASDAQ · Health careCardiol Therapeutics Inc. (CRDL)
It posted a net loss of CA$33.8M. In fiscal 2025 capital spending exceeded operating cash flow by CA$23.9M. At December 31, 2025 it held CA$21.4M in cash. Its latest periodic report to the SEC is the annual report (Canadian issuer) (40-F) filed on March 31, 2026.
What Cardiol Therapeutics Inc. does
Cardiol Therapeutics Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CRDL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -CA$33.8M | -CA$0.39 | -CA$23.9M |
| 2024 | n/a | -CA$36.7M | -CA$0.51 | -CA$25.1M |
| 2023 | n/a | -CA$28.1M | -CA$0.44 | -CA$25.2M |
| 2022 | n/a | -CA$30.9M | -CA$0.49 | -CA$27.3M |
| 2021 | CA$78.8K | -CA$31.6M | -CA$0.73 | -CA$23.6M |
| 2021 | n/a | -CA$20.6M | -CA$0.69 | -CA$9.2M |
Latest SEC filings
What Cardiol Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 23, 2026Passive stake changed SCHEDULE 13G/A
- September 23, 2026
- September 16, 2026Form SUPPL filing SUPPL
- September 16, 2026Form F-10/A filing F-10/A
- September 16, 2026
- September 15, 2026
- September 11, 2026
- September 10, 2026
- September 10, 2026Form F-X filing F-X
- September 10, 2026Form F-10 filing F-10
Insider trades
What the people running Cardiol Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about CRDL
What does Cardiol Therapeutics Inc. do?
Cardiol Therapeutics Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CRDL.
Is Cardiol Therapeutics Inc. profitable?
No. In fiscal 2025 it reported a net loss of CA$33.8M.
When did Cardiol Therapeutics Inc. last report?
Its most recent periodic report is the annual report (Canadian issuer) (40-F) filed on March 31, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the passive stake changed from September 23, 2026.
Similar companies
Compare CRDL with
Follow CRDL
Get an email when Cardiol Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow CRDL: get an email when it filesWhere the numbers come from
Financial figures are the values Cardiol Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.